Cargando…
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial
BACKGROUND: Elobixibat is an oral treatment candidate for chronic constipation with a novel mechanism of action via inhibition of the ileal bile acid transporter. We performed this randomized, double-blind, placebo-controlled, dose-finding phase IIb study in Japanese patients with chronic constipati...
Autores principales: | Nakajima, Atsushi, Seki, Mitsunori, Taniguchi, Shinya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866829/ https://www.ncbi.nlm.nih.gov/pubmed/28840422 http://dx.doi.org/10.1007/s00535-017-1383-5 |
Ejemplares similares
-
Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019) -
Internet survey on the actual situation of constipation in the Japanese population under 70 years old: focus on functional constipation and constipation-predominant irritable bowel syndrome
por: Kawamura, Yurika, et al.
Publicado: (2019) -
Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey
por: Marasco, Giovanni, et al.
Publicado: (2020) -
Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases
por: Zhang, Hu, et al.
Publicado: (2020) -
Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study
por: Kasugai, Kunio, et al.
Publicado: (2019)